2 results
Approved WMOCompleted
Primary objective:To characterize the clearance pathways, the route of excretion and the total recovery of radioactivity, PBI-4050 and its major metabolites in healthy subjects following administration of a single oral dose of 1200 mg [14C]-PBI-4050…
Approved WMORecruiting
the Sponsor aims to investigate if JDQ443 will stop abnormal cell growth related to the marker KRAS G12C mutation in patients with NSCLC whose tumors have specific characteristics, such as the presence of a KRAS G12C mutation, as well as the…